Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-20
2010-10-26
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C548S194000, C549S059000
Reexamination Certificate
active
07820704
ABSTRACT:
The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
REFERENCES:
patent: 5463071 (1995-10-01), Himmelsbach et al.
patent: 5470855 (1995-11-01), Bernat et al.
patent: 5502025 (1996-03-01), Bussler
patent: 5627131 (1997-05-01), Shribbs et al.
patent: 5643932 (1997-07-01), Chihiro et al.
patent: 6011048 (2000-01-01), Mathvink et al.
patent: 6303749 (2001-10-01), Jarosinski
patent: 6344470 (2002-02-01), Fontaine et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6689873 (2004-02-01), Van der Ploeg et al.
patent: 6699896 (2004-03-01), Malamas
patent: 6734175 (2004-05-01), Hadcock et al.
patent: 6787542 (2004-09-01), Wang et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 2002/0132807 (2002-09-01), Wang et al.
patent: 2002/0151463 (2002-10-01), Woychik et al.
patent: 2003/0082737 (2003-05-01), Stark et al.
patent: 2003/0158199 (2003-08-01), Stieber et al.
patent: 2004/0132788 (2004-07-01), Chabrier De Lassauniere et al.
patent: 2005/0009891 (2005-01-01), Lee
patent: 2005/0014746 (2005-01-01), Wang et al.
patent: 2005/0014805 (2005-01-01), Zhang et al.
patent: 2005/0038087 (2005-02-01), Chabrier De Lassauniere et al.
patent: 2005/0065196 (2005-03-01), Inaba et al.
patent: 2005/0261305 (2005-11-01), Das et al.
patent: 0 354 201 (1990-02-01), None
patent: 0 480 902 (1992-04-01), None
patent: 0 556 396 (1993-08-01), None
patent: 0 627 423 (1995-09-01), None
patent: 1 285 658 (2003-02-01), None
patent: 1 452 530 (2004-09-01), None
patent: 1 553 091 (2004-09-01), None
patent: 63203672 (1988-08-01), None
patent: 07149745 (1995-06-01), None
patent: WO 93-17681 (1993-09-01), None
patent: WO 97-47299 (1997-12-01), None
patent: WO 99-50295 (1999-10-01), None
patent: WO 99-58511 (1999-11-01), None
patent: WO 99-58514 (1999-11-01), None
patent: WO 00-11954 (2000-03-01), None
patent: WO 01-58871 (2001-08-01), None
patent: WO 02-02539 (2002-01-01), None
patent: WO 03-040117 (2003-05-01), None
patent: WO 03-068738 (2003-08-01), None
patent: WO 2004-004447 (2004-01-01), None
patent: WO 2006-038594 (2006-04-01), None
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids” Advanced Drug Delivery Reviews, 2004, vol. 56, pp. 275-300.
Database Chemcats, Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Order Nos: Q-084349, Q-084359 abstract, “Ambinter Stock Screening Collection”, Quai Louis Beriot, (2004).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 14989 abstract, UKR.KHIM. ZH et al., vol. 25, pp. 767-771 (1959).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 7541410 abstract & Farmaco, vol. 51, No. 2, pp. 137-140, (1996).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 678128 abstract & Eur. J. Med. Chem. Chim. Ther. vol. 9, p. 11, (1974).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 309225 abstract & J. Am. Chem. Soc. vol. 63, p. 3028 (1941).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 644518 abstract & Chem. Pharm. Bull., vol. 35 No. 12 pp. 4705-4710, (1987).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 687549 abstract & Chem. Heterocycl. Compd., vol. 2, p. 1181, (1976).
Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Maine, Database accession No. BRN: 294410 abstract & Justus Liebigs Ann. Chem., vol. 467, p. 254, (1928).
Database Beilstein, Beilstein Institute for Organic Chemisgtry, Frankfurt-Maine, Database accession No. BRN: 326592 abstracts & J. Indian Chem. Soc., vol. 32, pp. 663-665, (1955).
Database Beilstein, Beilstein Institute for Organic Chemisgtry, Frankfurt-Maine, Database accession No. BRN: 2991 abstract & J. Am. Chem. Soc., vol. 72, 1950, p. 3138, (1950).
Database Beilstein, Beilstein Institute for Organic Chemisgtry, Frankfurt-Maine, Database accession No. BRN: 4957 abstract & Yakugaku Zasshi, Vo. 71, p. 1439, (1951).
Database Beilstein, Beilstein Institute for Organic Chemisgtry, Frankfurt-Maine, Database accession No. BRN: 13161 abstract & Helv. Chim. Acta., vol. 31, p. 1142, (1946).
International Search Report for PCT application PCT/US2005/013386 mailed Aug. 26, 2005.
Adan et al., “Inverse agonism gains weight” Trends in Pharmacological Sciences, vol. 24, pp. 315-321, (2003).
Argyropoulos et al., “A polymorphism in the human agouti-related protein is associated with late-onset obesity” The Journal of Clinical Endocrinology & Metabolism, vol. 87, pp. 4198-4202, (2002).
Bednarek et al., “Selective, high affinity peptide antagonists of α-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro” Journal of Medicinal Chemistry, vol. 44, pp. 3665-3672, (2001).
Bolin et al., “NMR structure of a minimized human agouti related protein prepared by total chemical synthesis” FEBS Letters, vol. 451, pp. 125-131, (1999).
Brown et al., “The gene structure and minimal promoter of the human agouti related protein” Gene, vol. 277, pp. 231-238, (2001).
Bures et al., “Determination of disulfide structure in agouti-related protein (AgRP) by stepwise reduction and alkylation” Biochemistry, vol. 37, pp. 12172-12177, (1998).
Chai et al., “Inverse agonist activity of agouti and agouti-related protein” Peptides, vol. 24, pp. 603-609, (2003).
Claycombe et al., “Regulation of leptin by agouti” Physiological Genomics, vol. 2, pp. 101-105, (2000).
Cupples, “Peptides that regulate food intake” American Journal of Physiology, Regulatory, Integrative and Comparative Physiology, vol. 284, pp. R1370-R1374, (2003).
Dinulescu et al., “Agouti and agouti-related protein: analogies and contrasts” The Journal of Biological Chemistry, vol. 275, pp. 6695-6698, (2000).
Edwards et al., “Cocaine- and amphetamine-regulated transcript, glucagon-like peptide-1 and corticotrophin releasing factor inhibit feeding via agouti-related protein independnent pathways in the rat” Brain Research, vol. 866, pp. 128-134, (2000).
Fong et al., “ART (Protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors” Biochemical and Biophysical Research Communications, vol. 237, pp. 629-631, (1997).
Hanada et al., “Differential Regulation of Melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system” Biochemical and Biophysical Research Communications, vol. 268, pp. 88-91, (2000).
Harrold et al., “Changes in hypothalamic agouti-related protein (AgRP), but not α-MSH or pro-apiomelanocortin concentrations in dietary-obese and food restricted rats” Biochemical and Biophysical Research Communications, vol. 258, pp. 574-577, (1999).
Haskell-Luevano et al., “Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor” Regulatory Peptides, vol. 99, pp. 1-7, (2001).
Haskell-Luevano et al., “Structure activity studies of the melanocortin-4 receptor by in vitro Mutagenesis: identification of agouti-related protein (AgRP), Melanocortin agonist and synthetic peptide antagonist interaction determinantsȁ
Andrews Robert C.
Arimilli Murty N.
Dankwardt John
Gaddam Bapu R.
Mjalli Adnan M. M.
Kilpatrick & Stockton LLP
Kosack Joseph R
TransTech Pharma, Inc.
LandOfFree
Substituted heteroaryl derivatives, compositions, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heteroaryl derivatives, compositions, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heteroaryl derivatives, compositions, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155487